57 active not recruiting. 57 Phase 1, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 57 | Active not recruiting 57 |
| Phase 2 | 16 | Active not recruiting 16 |
Follow Sample Collection: new trials by email Literature Review of Sample Collection trials Research Report on Sample Collection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging - Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma | Phase 1 | Active not recruiting | Children's Oncology Group | 54 | 2025-06-18 | 2026-08-17 |
| TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2025-03-12 | 2026-10-16 |
| Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis Aldesleukin, Biopsy Procedure, Biospecimen Collection - Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma | Phase 1 | Active not recruiting | Mayo Clinic | 15 | 2023-11-29 | 2026-07-01 |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Biopsy Procedure, Biospecimen Collection, Cobimetinib - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2023-09-14 | 2026-10-09 |
| Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2023-05-22 | 2026-07-10 |
| Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers Biospecimen Collection, Computed Tomography, Ipatasertib - FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 96 | 2023-03-31 | 2026-10-01 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Atezolizumab, Biospecimen Collection, Computed Tomography - Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-11-17 | 2026-07-14 |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography - Recurrent AL Amyloidosis, Refractory AL Amyloidosis | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-08-03 | 2026-07-31 |
| Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2022-07-27 | 2026-05-13 |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-09-22 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Biospecimen Collection, Computed Tomography, Elimusertib - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 7 | 2022-07-06 | 2026-08-21 |
| Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome Biospecimen Collection, Computed Tomography, Duvelisib - Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 38 | 2021-10-21 | 2026-07-31 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-10-20 | 2026-09-10 |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 10 | 2021-08-13 | 2026-08-21 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Neuroendocrine Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-07-22 | 2026-06-15 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
| Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Berzosertib, Biospecimen Collection, Carboplatin - Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2021-04-14 | 2026-09-21 |
| Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2021-03-01 | 2026-07-31 |
Showing 20 of 57. Sign in to see all of them.
Neoplasm Metastasis (11) · Lung Neoplasms (5) · Pancreatic Neoplasms (5) · Breast Neoplasms (4) · Colorectal Neoplasms (4) · Fallopian Tube Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Leukemia, Myeloid, Acute (3) · Ovarian Neoplasms (3) · Small Cell Lung Carcinoma (3) · Stomach Neoplasms (3) · Urinary Bladder Neoplasms (3) · Astrocytoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2)
National Cancer Institute (NCI) (54) · Children's Oncology Group (1) · Mayo Clinic (1) · NRG Oncology (1)
United States (57) · Canada (12) · Australia (1) · Puerto Rico (1)
Liza C Villaruz (3) · Joyce F Liu (2) · Sarah E Taylor (2) · Timothy A Yap (2) · A P Chen (1) · Alex F Herrera (1) · Andrea B Apolo (1) · Anish Thomas (1) · Anna Spreafico (1) · Beth A Christian (1) · Brian A Jonas (1) · Catherine S Diefenbach (1) · Cynthia X Ma (1) · Diwakar Davar (1) · Dwight H Owen (1)
PMID 23810467, PMID 25218906, PMID 31151904, PMID 32853585, PMID 32915679, PMID 35031545, PMID 35205614, PMID 35264434, PMID 35622074, PMID 37185961, PMID 37505794, PMID 38236249, PMID 38737792, PMID 38934093, PMID 38954785, PMID 39673591, PMID 39841295, PMID 40226119, PMID 40721981, PMID 41206673, PMID 41662628, PMID 42518206
UM1CA186689 (9), UM1CA186644 (7), UM1CA186709 (7), UM1CA186717 (7), UM1CA186690 (6), UM1CA186712 (6), UM1CA186704 (5), U01CA062490 (4), UM1CA186688 (4), UM1CA081457 (3), UM1CA186716 (3), P30CA006516 (2), P30CA016058 (2), U01CA076576 (2), U10CA180868 (2)